News & Media
|Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia|
|Jul 27 2015 -
Expansion of the trial to six sites across Canada and South Africa accelerates enrollment
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM), a clinical-stage autologous cell-therapy company, announced another milestone today in its international phase-2 clinical trial for critical limb ischemia (CLI): enrollment of its 20th patient. The double-blind, randomized, placebo-controlled trial currently recruits participants at six sites in Canada and South Africa under the same clinical protocol and will ultimately enroll approximately 100 participants with CLI.
The trial studies the efficacy of the company’s lead product, ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are grown from a patient’s own blood and, once injected into his or her diseased tissue, are able to support the formation of new blood vessels.
“Our clinical trial is enrolling participants at an accelerated pace as a direct result of our ability to continue recruiting clinical sites,” said Dr. Hardean E. Achneck, vice president of clinical research and operations at Hemostemix. “We enrolled 20 participants and have already treated 15, which is remarkable because five of our six clinical sites only began enrolling at the end of March.”
“This milestone demonstrates the strength of our clinical program and reflects our ability to deliver on our clinical development goals,” said Dr. Elmar Burchardt, president and CEO of Hemostemix. “It also attests to the need for a nonsurgical, regenerative cell therapy that addresses CLI. We are committed to relieving the suffering of patients with this severe and debilitating disease through our innovative cell therapy.”
For more information, please contact email@example.com